Kategoria BISAC: Medical >> Oncology - General

Information gathered from cell-free systems, cell cultures, animal models, and human studies, together will (1) provide important insights to our understanding of hormonal cancer causation, development, and prevention; (2) be the primary objective of these Symposia.

Proceedings of the 2nd Annual IFOM-IEO Meeting on Cancer. This is a new meeting, it has about 200 attendees from Australia, Austria, Belgium, Brazil, Canada, England, France, Germany, Greece, Ireland, Italy, Japan, Netherlands, Spain, Sweden, Switzerland, and the USA.

The 2nd IFOM-IEO international meeting on cancer will provide a forum in which the world's leading cancer researchers and young scientists will discuss the latest advances in molecular oncology. The impact of recent breakthroughs in basic research and of emerging technologies on molecular medicine in cancer will be...

Sentinel lymph node (SLN) procedures have opened a window of opportunity for the study of micrometastasis. In eighty percent (80%) of metastasis there lies an orderly pattern of progression via the lymphatic network, while 20% of the time systemic metastasis occurs, bypassing the lymphatic system. During the past two decades, significant progress has been achieved in understanding the anatomical, functional, cellular and molecular aspects of the lymphovascular system and the metastasis process.

. Molecular imaging advances help to localize early cancers more precisely.

....

Brain metastases are the most dreaded complication of systemic cancer, affecting approximately 170,000 people a year, a far greater incidence than primary brain tumors. Advances in modern chemotherapy have led to an improved control of system cancers, often with agents that poorly penetrate the central nervous system, resulting in an increasing incidence of brain metastases. Traditional chemotherapy has had little impact on brain metastases. The main therapeutic option is radiation therapy, and in a small number of patients - surgery. However, refinements in all of these treatments offer...

Since the previous M.D. Anderson Solid Tumor Oncology Series publication on pancreatic cancer, there have been major advances in our understanding of molecular events which underlie pancreatic cancer development, both in the sporadic and inherited forms. We have seen the development of the first mouse models that accurately recapitulate features of the human disease. Several landmark clinical trials in both resectable and metastatic pancreatic cancer have been completed, raising new questions about the standard of care in this disease. Finally, the era of targeted biologic therapies has...

Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as...

In September 2005 an International Meeting on "Targeted Therapies in Cancer: Myth or Reality" was held in Milan. This successful Meeting was intended to represent a forum for scientists and clinicians working in cancer drug discovery and therapy to share their reflections and experiences on how the paradigm shift from empiricism to molecular targeted therapies is contributing to the translation of basic knowledge into new therapies for cancer patients. This book collects the contributions given by scientists and clinicians, from Academia and Industry, who participated to this Meeting.